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Abstract
The aim of palliative chemotherapy is to increase survival whilst maintaining maximum quality of life
for the individual concerned. Although we are still continuing to explore the optimum use of
traditional chemotherapy agents, the introduction of targeted therapies has significantly broadened
the therapeutic options. Interestingly, the results from current trials put the underlying biological
concept often into a new, less favorable perspective. Recent data suggested that altered pathways
underlie cancer, and not just altered genes. Thus, an effective therapeutic agent will sometimes have
to target downstream parts of a signaling pathway or physiological effects rather than individual
genes. In addition, over the past few years increasing evidence has suggested that solid tumors
represent a very heterogeneous group of cells with different susceptibility to cancer therapy. Thus,
since therapeutic concepts and pathophysiological understanding are continuously evolving a
combination of current concepts in tumor therapy and tumor biology is needed. This review aims
to present current problems of cancer therapy by highlighting exemplary results from recent
clinical trials with colorectal and pancreatic cancer patients and to discuss the current
understanding of the underlying reasons.
Introduction
The aim of palliative chemotherapy is to increase survival
whilst maintaining maximum quality of life for the indi-
vidual concerned. The survival advantage offered by palli-
ative chemotherapy for metastatic cancer has increased
incrementally with the addition of each newly licensed
therapeutic agent [1]. Still, a number of cancer entities
escape these efforts [2]. More recently, advances in the
field have led to the introduction of targeted therapies,
whose benefits are documented in clinical trials and are
acknowledged in their approval and licensing [3-5].
Whilst we are still continuing to explore the optimum use
of the more traditional chemotherapy agents, with respect
to both quantity and quality of life, these novel agents are
trying to find their optimum place in the therapeutic
armamentarium. It is evident that a continuing add-one-
in policy is likely to be detrimental to both patient and
budget. Defining the positioning and duration of these
combination therapies has become the subject of much
debate and numerous current clinical trials. However, pre-
dictions of efficacy based on biological in vitro studies
have led to several disappointments lately. At the same
time, the understanding of tumor biology is continuously
evolving as well. Therefore it is urgently needed to com-
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bine results from current trials with current concepts of
tumor-biology in order to understand why therapeutic
concepts might fail and to possibly help to design future
trials more efficiently. This review aims to present and
combine current concepts and pitfalls of tumor therapy
and tumor biology. We will use exemplary data from cur-
rent trials mainly from colorectal and pancreatic cancer in
order to highlight current problems in tumor therapy.
This review does not attempt to cover all aspects related to
palliative chemotherapy or all aspects of targeted therapy.
Signal transduction networks and the response 
to cancer therapy
An underlying principle of anti-cancer combination
chemotherapy is that drugs, that function through sepa-
rate cytotoxic mechanisms and have different dose-limit-
ing adverse effects, can be administered together at full
doses, with a resulting superior outcome [1,2,6]. Parenter-
ally and orally administered fluoropyrimidines have been
given with irinotecan in regimens known as FOLFIRI (foli-
nic acid, fluorouracil, and irinotecan) [7] or CapIri
(capecitabine and irinotecan) [8] and with oxaliplatin in
combinations known as FOLFOX (folinic acid, fluorour-
acil, and oxaliplatin) or CapOx (capecitabine and oxalipl-
atin) [9,10]. The use of these drug combinations in
metastatic colorectal cancer has prolonged median sur-
vival from the 10-to-12-month range associated with
fluoropyrimidine therapy alone to more than 20 months.
The development of additional effective forms of chemo-
therapy for colorectal cancer has been possible by the
emergence of drugs directed against signaling molecules
that are thought to be important in the proliferation of
malignant cells [11-13]. This concept has been termed
"targeted therapies". Different strategies are available in
order to interfere with tumor-specific signal transduction
pathways. First the ligand of a given receptor can be tar-
geted. There, two modes of interference are used. i) an
antibody targeting the ligand itself (shown for bevacizu-
mab and the vascular endothelial growth factor (VEGF))
[14,15] ii) a decoy receptor competes with the target-
receptor for ligand binding (VEGFtrap) [16] or an anti-
body binds to the receptor, thereby preventing ligand
binding (shown for epithelial growth factor receptor
(EGFR) binding of cetuximab, panitumumab,
EMD72000, h-R3) [17-19]. Alternatively, if the enzyme is
to be targeted directly, small molecule inhibitors can be
used to interfere with either the substrate binding or with
the access to the ATP binding site (e.g. PTK/ZK, erlotinib,
gefitinib) [20-23]. Moreover, interfering RNA or DNA
molecules can be given systemically in order to posttrans-
lationally inhibit expression of a given gene [24].
Although there is an increasing number of drugs directed
towards an equally growing number of target proteins the
most commonly used inhibitors are directed against EGFR
derived signals (i.e. cetuximab, panitumumab, erlotinib)
or VEGF mediated effects (i.e. bevacizumab). Accordingly
the use of drugs interfering with these signaling modules
has been tested in several trials and we will focus exempla-
rily on results obtained in colorectal and pancreatic can-
cer.
Numerous in vitro studies have defined multiple compo-
nents of the EGFR signaling pathway and generated data
showing that one or more of these components are com-
monly activated in colorectal cancer [25,26]. These find-
ings led to preclinical and then clinical trials of EGFR
inhibitors. Inhibitors that bind to the EGFR and prevent it
from performing its function, namely cell signaling, have
been shown to modestly improve progression-free sur-
vival, overall survival, and the quality of life among
patients with pretreated colorectal cancer [5,27]. Interest-
ingly, the degree of expression of the EGFR in colorectal
cancers, as estimated by immunohistochemical analysis,
does not appear to predict the efficacy of these antibodies
[28,29]. KRAS is a guanosine triphosphate (GTP) hydro-
lyzing protein that acts as a critical on-off switch in cellu-
lar growth and survival pathways [12]. It is a central
component of the mitogen-activated protein kinase
(MAPK) pathway, which is one of the pathways activated
by EGFR signaling [30]. Mutations of KRAS occur in about
40% of colorectal cancers [31]. Recent data suggests that
both cetuximab and panitumumab are effective only in
the treatment of colorectal tumors with a wild-type KRAS
gene; patients with tumors harboring mutations in KRAS
are resistant to the two EGFR inhibitors [5,32-35]. In addi-
tion, in a recent study mutations were detected in 10% of
the patients in the RAS-activated kinase BRAF [36]. Muta-
tions in the RAS and RAF genes are mutually exclusive
[37]. None of the patients with tumors exhibiting BRAF
mutations responded to an EGFR antibody treatment,
wheras none of the responders to the treatment had BRAF
mutations [38]. However, not only KRAS and BRAF as
immediate downstream targets of the EGFR modulate
responsiveness to anti-EGFR therapies. The expression sta-
tus of the phosphatase and tensin homolog (PTEN) may
also affect the clinical response in cetuximab-treated met-
astatic colorectal cancer patients [39]. In a recent study 27
cetuximab-treated patients were evaluated for drug
response. Interestingly, the PTEN protein was normally
expressed in 16 patients, and in 10 of them a partial
response was achieved. In contrast, no benefit was docu-
mented in 11 patients with loss of PTEN activity (P <
0.001) [40]. Similarly levels of other growth factors such
as epiregulin and amphiregulin influence the disease con-
trol under cetuximab therapy in KRAS wild type tumors
[41]. It can be assumed that alterations of more and more
proteins (the data mentioned above are only a part of the
available data) will be identified that interfere with EGFR
signaling and other targeted signaling pathways and that
an individualized assessment of eligibility is needed in theCell Communication and Signaling 2009, 7:19 http://www.biosignaling.com/content/7/1/19
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future in order to identify patients that benefit from ther-
apeutic efforts (Figure 1).
Rooted in the belief that blocking blood vessel supply
starves tumors to death [14], it has become increasingly
accepted that blocking tumor angiogenesis as much as
possible would provide cancer patients with maximum
survival benefit. Given the key importance of VEGF and its
receptor VEGFR2 in angiogenesis, hopes were raised that
blocking this pathway would eradicate the tumor vascula-
ture and cure cancer. Indeed, the monoclonal anti-VEGF
antibody bevacizumab [42,43] and the second-generation
multitargeted receptor tyrosine kinase inhibitors (RTKIs)
sunitinib [23,44] and sorafenib [3,45] have prolonged the
life of numerous cancer patients. Since combining cyto-
toxic drugs that act through different mechanisms
improved outcomes in patients with metastatic colorectal
cancer, it seemed logical that further benefit would result
from combining bevacizumab with either cetuximab or
panitumumab and administering these monoclonal anti-
bodies together with chemotherapy. This assumption was
supported by preclinical studies and a phase II clinical
trial in 40 patients, that suggested that the bevacizumab-
cetuximab combination is associated with acceptable
rates of adverse effects [46]. A recent phase III trial con-
ducted in the Netherlands included 732 patients with pre-
viously untreated metastatic colorectal cancer who were
randomly assigned to receive capecitabine, oxaliplatin,
and bevacizumab in cycles administered every 3 weeks or
the same regimen supplemented with weekly cetuximab
Exemplary components of the EGFR und VEGR dependent signal transduction pathways Figure 1
Exemplary components of the EGFR und VEGR dependent signal transduction pathways. The compounds/drugs 
indicated in the green boxes next to the receptors/kinases indicate substances for interference. The white boxes contain the 
percentages of mutated or altered proteins known to be present in pancreatic cancer (PC) or colorectal cancer (CRC).Cell Communication and Signaling 2009, 7:19 http://www.biosignaling.com/content/7/1/19
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[47]. After a median follow-up of 23 months, the surpris-
ing result was that the addition of cetuximab to the com-
bination of capecitabine, oxaliplatin, and bevacizumab
significantly decreased the median progression-free sur-
vival time from 10.7 months to 9.4 months; the addition
of cetuximab was also associated with a trend toward
reducing the median overall survival, from 20.3 months
to 19.4 months. Tumor tissue was assessed for the status
of the KRAS gene in 71% of patients and mutations were
found in 40% of the specimens. The addition of cetuxi-
mab did not improve the outcome in patients whose
tumors contained wild-type KRAS and was also deleteri-
ous for those with tumors bearing a mutant KRAS gene.
The rate of adverse events was similar in the two treatment
cohorts after the exclusion of cetuximab-related adverse
cutaneous effects. The negative effect of adding an anti-
EGFR antibody to a chemotherapy-bevacizumab combi-
nation (CBC) has also been observed by an American
study in the Panitumumab Advanced Colorectal Cancer
Evaluation (PACCE) trial, in which 823 patients who had
not received previous treatment for metastatic colorectal
cancer were randomly assigned to receive FOLFOX and
bevacizumab, either alone or accompanied by panitumu-
mab [48]. The addition of panitumumab reduced both
the median progression-free survival and the median
overall survival. At present, there is no obvious explana-
tion for these unanticipated data. The negative effect of
combining anti-VEGF and anti-EGFR monoclonal anti-
bodies seems to occur when the two antibodies are
administered with chemotherapy regimens that contain
either oxaliplatin or irinotecan. The negative effect cannot
be attributed to limited treatment intensity due to adverse
events, since tolerance of the treatment was indistinguish-
able in the two groups in the study by Tol et al. [47]. Both
Tol et al. and Hecht and colleagues [48] speculate that an
unexpected interaction between the two monoclonal anti-
bodies occurred, but no mechanism has yet been identi-
fied. These data serve as a reminder that antitumor activity
observed in preclinical and also uncontrolled clinical con-
texts may not be validated when put to the test in rand-
omized trials. Furthermore, the data suggest that
combining multiple forms of targeted therapies may not
be analogous to combining different types of cytotoxic
chemotherapy, presumably because of unrecognized
interactions of intracellular signaling pathways. Finally,
these results underscore the fundamental importance of
subjecting hypotheses to carefully conducted clinical tri-
als. As was observed in these examples, more is not always
better.
In contrast to colorectal cancer, there has been no signifi-
cant improvement of overall survival by chemotherapy in
pancreatic cancer patients. However, after a study pre-
sented by Burris et al. gemcitabine was established as the
gold-standard in the treatment of pancreatic cancer [49].
This study comparing gemcitabine with 5-FU mono-
therapy showed only a moderate increase in median sur-
vival (5.7 months vs. 4.4 months, 1-year survival 18% vs.
2%), but a significant improvement in a new parameter,
the so called „clinical benefit response“ (CBR; 23.8% vs.
4.8%). CBR is a construct of a number of parameters
including pain-intensity, use of analgetics, functional
impairment and change of body-weight. In several con-
firmatory phase III-trials monotherapy with gemcitabine
showed a median survival of 5 to 6.5 months with a 1-year
survival of about 11–25%. Many subsequent trials have
tested numerous combinations of various cytotoxic agents
in the treatment of pancreatic cancer but failed to signifi-
cantly improve survival [50]. Therefore, the combination
of conventional chemotherapy with targeted therapy
seemed promising. The EGFR and its ligands are overex-
pressed in more than 50% of pancreatic cancers. But
blocking the EGFR by treatment with the chimeric anti-
body cetuximab in combination with gemcitabine did not
lead to a significant increase in tumor response, progres-
sion-free and overall survival [51]. However, a subsequent
phase III study was able to show a significant increase in
progression-free survival (3.55 vs. 3.75 months) and over-
all survival (5.91 vs. 6.24 months) by a combination of
erlotinib, a small molecule inhibitor of the receptor tyro-
sine kinase activity of the EGFR, and gemcitabine (HR
0.82, p = 0.038) [52]. Taken the high patient numbers
into account (> 280 patients per arm) these small differ-
ences were enough to reach statistical significance. Inter-
estingly, a sub-group analysis was able to show, in good
agreement with the data obtained in colorectal cancer,
that patients developing a skin reaction (rash) ≥ grade II
had an improved median survival under combination
therapy compared to patients with no skin reaction (10.5
vs. 5.3 months). Another interesting aspect was the
improved efficacy in patients with impaired performance
status (ECOG 2). However, from a clinical point of view it
is not as clear how relevant and meaningful a difference of
about 2 weeks in overall-survival, and about 8 days in pro-
gression-free survival really is.
As already stated before, in the treatment of colorectal
cancer, the combination of a conventional chemotherapy
with bevacizumab was able to significantly increase
median survival. An analogous phase III study investigat-
ing a combination of gemcitabine and bevacizumab in
pancreatic cancer (CALGB 80303) was stopped after an
interim analysis made an increase in overall survival, the
primary endpoint, by the combination therapy unlikely
(Kindler et al., Proc ASCO 2007; #4508 (abstract)). The
promising data from a non-randomized phase II study
could obviously not be reproduced (median survival 8.8
months, 1-year survival 29%) in a larger cohort [53]. In
analogy to the colorectal cancer trials, double targeting
was analyzed in pancreatic cancer as well. The recentCell Communication and Signaling 2009, 7:19 http://www.biosignaling.com/content/7/1/19
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AVITA (BO17706) study was a randomized, double-
blind, placebo-controlled phase III study that included
607 patients with metastatic pancreatic cancer. Patients
received first-line treatment with either gemcitabine, erlo-
tinib and placebo or gemcitabine, erlotinib and bevacizu-
mab (at 5 mg/kg every two weeks). However, the study
did not meet its primary endpoint of improved overall
survival (OS) (6.0 vs. 7.1 months), although results
showed a slightly improved progression-free survival (3.6
vs. 4.6 months). In addition, further analysis confirmed
that skin rash > grade II translated into an increased over-
all survival [54].
Although it remains speculative why double targeting fails
to fulfill the predicted increase in efficacy in several cancer
types, recent data provide possible explanations. In a
series of elegant papers it was shown that VEGF-targeted
drugs inhibit primary tumor growth, yet may shorten sur-
vival of mice by promoting tumor invasiveness and
metastasis [55,56]. One plausible mechanism for this
phenomenon is tumor hypoxia. Unlike normal cells,
tumor cells are able to cope with hypoxia more effectively
[57]. Apart from metabolic preference for glucose, which
allows tumor cells to generate energy under hypoxic con-
ditions, hypoxia-tolerant tumor cell clones are selected,
while tumor stem cells in hypoxic niches might escape
antiangiogenic treatment as well. Hypoxia thus may select
for more malignant metastatic cells, which are less sensi-
tive to antiangiogenic treatment [58]. In support of this
concept, treatment of mice with anti-VEGFR2 induces a
shift in the glioblastoma tumor phenotype toward
enhanced migration and invasion [59]. In addition,
tumors devise other vascular supply mechanisms, that are
not always inhibited by VEGF-targeted therapy [60], such
as the recruitment of angiocompetent bone marrow-
derived cells [61] or the co-option of existing vasculature.
How these concepts are in line with current clinical stud-
ies is yet to be determined, but further evidence from
whole genome analysis of various cancers suggests that
effective targeting of individual pathways is probably
more difficult than previously suspected [62-64]. In a
recent study 20,661 protein coding genes from 24 human
pancreatic adenocarcinomas were subjected to genomic
analysis to identify changes that occur in the DNA, includ-
ing SNPs [62]. A typical pancreatic cancer shows 63
genetic alterations, which are mostly point mutations, but
many more than 63 genes are involved overall. Of all the
genes sequenced, 1327 showed at least 1 mutation, and
148 showed 2 or more mutations in the pancreatic tumor
samples. Among the 24 pancreatic cancers studied, 69
gene sets were altered in the majority of tumors. These
could be grouped into 12 "core signaling pathways and
processes" that each individually affected 67% to 100% of
the 24 tumors. Some pathways involved a single altered
gene, in others 2 or 3 predominant genes were altered,
and other pathways showed alteration of many genes.
This in-depth genomic analysis suggested that altered
pathways underlie pancreatic cancer and not only altered
genes [62]. Thus, for many cancer types, an effective ther-
apy will have to also target downstream parts of these
pathways or their physiological effects, such as metabolic
functions, expression of cell surface proteins, or changes
in the cell cycle, rather than just individual genes.
Metastasis, cancer stem cell heterogeneity and 
the response to cancer therapy
Metastasis, the major cause of mortality in patients with
cancer, is caused by tumor cells that escape from the pri-
mary tumor into the bloodstream and travel through the
circulation to distant sites where they develop into sec-
ondary tumors. Although these circulating tumor cells
(CTCs) provide a link between the primary tumor and
metastatic sites, the factors involved in successful survival
and eventual formation of metastases are not well under-
stood [65,66]. The number of studies presenting new
insights into the mechanisms of colorectal cancer metas-
tases is growing continuously [67-69]. However, it is
increasingly appreciated that the number of cells that
reach the bloodstream is far greater than the number of
metastases [70]. Therefore specific sub-populations of
CTCs might be responsible for successful dissemination of
cancer cells within an organism.
Over the past few years increasing evidence has suggested
that stem cells may play a crucial role in the development
and progression of tumors. Distinct populations of cells
with stem cell properties may be essential for the develop-
ment and perpetuation of various human cancers [71-73].
According to the current definition, a cancer stem cell
(CSC) represents a cell within a tumor that is able to self-
renew, is exclusively tumorigenic, and is capable of pro-
ducing the heterogeneous lineages of cancer cells that
comprise the tumor (Figure 2). In human colorectal can-
cer a subpopulation of cells with certain surface markers
(i.e. CD133+, CD44+ or ESA+ phenotypes) are thought to
be uniquely responsible for tumorigenesis and to have the
capacity to generate heterogeneous tumors in a xenograft
setting. Interestingly, the selection is based on markers
that do not have any functional relevance for being a CSC,
and the exclusiveness of the CSC population in the ability
to initiate cancer as well as its uniqueness in CD133 posi-
tivity has been questioned recently [74]. Moreover, recent
data suggest that CD133 expression is beyond the rare
primitive cells; it rather seems to be a general marker of
apical or apicolateral membranes of glandular epithelia
[75]. Thus, although it is possible to identify new subsets
in cancer cell populations it is increasingly clear that nei-
ther the markers for identification nor the underlying
mechanisms are sufficiently understood [76,77].Cell Communication and Signaling 2009, 7:19 http://www.biosignaling.com/content/7/1/19
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In addition, a specific subpopulation of migrating CSCs
has been identified recently and has been attributed with
the responsibility for tumor metastasis [72,78]. The stro-
mal-derived factor (SDF)-1(alpha) and the CXC receptor
(CXCR)-4 jointly regulate the trafficking of various cell
types and play a pivotal role in the migration of hemato-
poetic cells. A fundamental role of CXCR4 in metastatic
spreading has also been suggested for a variety of cancers
[79-82]. Interestingly, the distant organ sites most com-
monly affected by metastases are lymph nodes, lung, liver
and bone marrow, all of which exhibit a high content of
SDF-1, the natural ligand for CXCR4 [83]. AMD3100, a
specific pharmacological inhibitor of the CXCR4 receptor,
is currently evaluated in clinical phase I and II trials. The
finding that AMD3100 potently inhibits the metastatic
activity of unselected murine pancreatic cancer cells [84]
as well as other cancer cells [85,86], and the fact that
AMD3100 is already evaluated in ongoing clinical trials
make it a promising candidate for further experimental
studies on CSC-mediated metastasis [87].
Cancer treatment has traditionally been based on the
implicit assumption that human cancer populations are
homogeneous. A cancer is resilient to treatment because
malignant cells survive chemotherapy and radiation or
avoid immune surveillance [88]. It has been suggested
that the CSC population might be responsible for the
resistance of certain tumors to therapy (Figure 2) [89,90].
Gene expression studies revealed a higher expression of
DNA mismatch repair genes such as MGMT, as well as
genes that inhibited apoptosis in the CD133-expressing
cancer stem cells. These included antiapoptotic genes such
as FLIP, BCL-2, and BCL-XL [91]. The inhibitor of apopto-
sis protein family (IAP) genes such as XIAP, cIAP1, cIAP2,
Possible roles of cancer stem cells (CSC) over the course of the disease Figure 2
Possible roles of cancer stem cells (CSC) over the course of the disease. Cancer stem cells give rise to the different 
lines of a given tumor. During chemotherapy cancer stem cells are more resistant due to expression of multi-drug-resistance 
genes.Cell Communication and Signaling 2009, 7:19 http://www.biosignaling.com/content/7/1/19
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NAIP, and survivin were also found at higher expression
levels in CD133+ cells. These results were consistent with
and support the results of chemoresistance, in which
CD133+ cells showed significant resistance to common
chemotherapeutic drugs compared with autologous
CD133- cells [92]. Interestingly, one way to characterize
the CSC population in flow cytometry assays is by
Hoechst® dye exclusion [93]. This assay has been com-
monly used as one of the methods to enrich for cancer
stem cells in cancer cell lines and primary tumor cultures
[94]. Goodell et al. have demonstrated that the exclusion
of Hoechst® dye by CSC is a dynamic process involving the
multidrug resistance transporter 1 (MDR1), a member of
the ABC transporter transmembrane proteins [95]. MDR1
is certainly not the only transporter present on CSCs since
alternative proteins such as the BCRP1 multidrug resist-
ance transporter has been shown to be a molecular deter-
minant of mouse hematopoietic stem cells [96]. Thus, it
has to be hypothesized that if non-tumorigenic cells are
more susceptible to chemotherapeutic agents, residual
tumors after chemotherapy might contain a higher fre-
quency of CSC. Indeed recent data from individual tumor
phenotypic analysis and serial transplants suggest that
residual tumors after conventional chemotherapy are
enriched for cells with a CSC phenotype and have an
increased tumorigenic cell frequency [97-99].
These emerging data emphasize the urgent need for either
developing targeted therapies against CSCs or modifying
current treatment modalities in order to eliminate these
cells. Recent studies implicate the Notch signaling path-
way as a possible target [100-103]. Using inhibitors of
Notch (e.g. OMP-21M18, a humanized monoclonal anti-
body specific to delta-like 4 (DLL4)), depletion of the spe-
cific brain CSC population defined by the CD133 marker
or an ability to efflux the Hoechst® dye was shown [104].
Notch was also expressed more highly in the stem cell-like
fraction, providing a potential mechanism for their
increased sensitivity to inhibition of this pathway. This
depletion of the stem cell fraction resulted in a loss of
tumor-forming capacity. Apoptotic rates following Notch
blockade were increased almost 10-fold in primitive nes-
tin-positive, stem-like cells compared with nestin-nega-
tive cells. In addition to that, there is an increasing
number of therapeutic strategies specifically targeting the
CSC fraction [105]. One further example is parthenolide
– a sesquiterpene lactone compound found in Feverfew
(Tanacetum parthenium), a traditional medicinal herb
that has been used for migraine and rheumatoid arthritis
[106]. Parthenolide was shown to have antiproliferative
activity on CSCs and is thought to act through inhibition
of NF-κB [107].
Other concepts are in the process of evaluation in vitro
and in vivo: ARH460-16-2, is a therapeutic antibody tar-
geting CD44 [108], RAV-17 targets another surface mole-
cule of CSCs called B7-H3, GRN163L directly targets the
active site of human telomerase and antagonizes telom-
eric DNA substrates [109], and SL-401 is a chimeric pro-
tein comprised of diphtheria toxin fused with the protein
IL-3 that appears to be cytotoxic to CSCs is in phase I clin-
ical development [110].
Conclusion
Taken together, the data presented here emphasize that
the development of new treatment strategies is a time con-
suming and cumbersome process. The results from cur-
rent trials suggest that new concepts are needed in order to
achieve a further increase in survival for these often dele-
terious diseases. Our understanding of cancer cell biology
as well as cancer stem cell biology needs to be deepened
in order to identify new targets. A major challenge for the
development of new therapeutic agents will be the neces-
sity to discriminate between CSCs and normal stem cells.
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